Regeneron should weather the Eylea biosimilar launch storm and continue to deliver long-term shareholder value. See why REGN ...

U.S. drugmaker Regeneron Pharmaceuticals beat Wall Street estimates for third-quarter profit and revenue on Thursday, driven ...

Despite disappointing third-quarter results for Regeneron’s high-dose Eylea injection, analysts continued to be cautiously ...

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming.

and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and ...

Regeneron has leveraged its monoclonal ... With the recent EU approval in chronic obstructive pulmonary disease, we now model $21 billion in peak Dupixent sales by 2029. While the partnership ...

Keep abreast with the latest news related to Chronic Obstructive Pulmonary Disease there are 1811 news items on Chronic Obstructive Pulmonary Disease that covers updates, breakthroughs and in ...

Regeneron reports better-than-expected third-quarter results, beating earnings and revenue estimates, driven by strong Eylea HD, Dupixent and Libtayo sales.

Regeneron's drug Dupixent received approval for treating Chronic Obstructive Pulmonary Disease in the U.S. and China, which TD Cowen believes could represent a $2-3 billion opportunity. However, ...

Sanofi to present dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria at ACAAI: Paris Saturday, October 26, 2024, 12:00 Hrs [IST] Positive data from the ...

and chronic obstructive pulmonary disease in different age populations. More than 1,000,000 patients are being treated with Dupixent globally. Dupilumab is being jointly developed by Regeneron and ...

Dupixent significantly reduced itch and hive activity from baseline; 41% of patients achieved well-controlled disease statusConfirmatory data to support US regulatory resubmission by year-end; if ...